Wedbush Securities appointed Laura Chico, SVP of equity research on the healthcare and biotech team.
Dr. Chico has more than a decade of experience in the biotechnology and drug discovery industry, as well as nine years in equity research. Prior to joining Wedbush, she served as VP of equity research at Raymond James, and previously was a biotech analyst in the Robert W. Baird equity research healthcare group.
Before entering equity research, Dr. Chico held scientific roles in both industry and academic settings with focus in central nervous system diseases, such as Alzheimer’s disease. She continues to serve as an adjunct assistant professor at Northwestern University’s Feinberg School of Medicine.
Dr. Chico’s addition represents Wedbush’s decades-long commitment to its healthcare and biotech practice, since its acquisition of Pacific Growth. She joins a team that includes David Nierengarten, Liana Moussatos, and Robert Driscoll.
In a statement, Don Hultgren, EVP, chief administrative officer, and interim director of research for Wedbush, said Dr. Chico’s history in CNS diseases, both from the equities research and scientific side, will help investors navigate complex scientific concepts, and further build the firm’s healthcare research offering.
